Train2Target

  • Project
  • Network
    • Beneficiaries
    • Partner Organisations
    • Members Area
  • People
    • Supervisors
    • Early Stage Researchers (ESR) >
      • ESR 1: Carlos Gurnani
      • ESR 2: Tiago Baeta
      • ESR 3: Mitja Zdouc
      • ESR 4: Raquel Rodriguez
      • ESR 5: Jessica El-Rayes
      • ESR 6: Laureen Mertens
      • ESR 7: Elisa Consoli
      • ESR 8: Matthias Winkle
      • ESR 9: Kara Staunton
      • ESR 10: Pilar García del Vello
      • ESR 11: Elisabete Cardoso
      • ESR 12: Valentina Lucchini
      • ESR 13: Arancha Lopez
      • ESR 14: Federico Corona
      • ESR 15: Carina Matias
    • Scientific Advisory Board
  • Training
    • Training Plan
    • Annual Meeting 2019
    • Annual Meeting 2018
    • Annual Meeting 2017
  • Research
    • Workplan
    • Publications
  • Conferences
  • News
  • Project
  • Network
    • Beneficiaries
    • Partner Organisations
    • Members Area
  • People
    • Supervisors
    • Early Stage Researchers (ESR) >
      • ESR 1: Carlos Gurnani
      • ESR 2: Tiago Baeta
      • ESR 3: Mitja Zdouc
      • ESR 4: Raquel Rodriguez
      • ESR 5: Jessica El-Rayes
      • ESR 6: Laureen Mertens
      • ESR 7: Elisa Consoli
      • ESR 8: Matthias Winkle
      • ESR 9: Kara Staunton
      • ESR 10: Pilar García del Vello
      • ESR 11: Elisabete Cardoso
      • ESR 12: Valentina Lucchini
      • ESR 13: Arancha Lopez
      • ESR 14: Federico Corona
      • ESR 15: Carina Matias
    • Scientific Advisory Board
  • Training
    • Training Plan
    • Annual Meeting 2019
    • Annual Meeting 2018
    • Annual Meeting 2017
  • Research
    • Workplan
    • Publications
  • Conferences
  • News

ESR 15: Carina Matias

Picture
Development of a novel anibiotic treatment

Carina is involved in the investigation of microbiological properties of novel drug ATx201 including (a) assessment of potency across clinically relevant pathogens, (b) investigation into mode of action, (c) characterization of potency in different synthetic genetic backgrounds, (d) assessment of resistance evolution properties relative to currently marketed products, (e) high throughput screens for identification of novel antibiotic treatments targeting human pathogens.

Host:
UNION Therapeutics, Denmark
Danish Technical University, Novo Nordisk Foundation Center for Biosustainability, Denmark

Supervisory Team:
Prof. Morten Sommer (DTU)
Prof. Ian Henderson (UNIBIR-IMI)
Prof. Jean-Pierre Simorre (CNRS)

Scientific Background:
Carina has acquired an interest for microbiology and antimicrobial resistance during her first degree in Health Sciences at the Insitute of Health Sciences Egas Moniz in Portugal (2009-2013). She subsequently finished her Master degree in Microbiology from the Technical University of Lisbon (2013-2015) with her master thesis “Quorum-sensing system of Staphylococcus aureus isolates from diabetic foot ulcers”.
Science Slam: What are antibiotics? Explained by Carina
Picture
Picture
​Contact:
carina.matias@uniontherapeutics.com

Picture
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 721484.

© accelopment Schweiz AG 2019. ALL RIGHTS RESERVED.
Disclaimer | Members Area